Feb 12, 2010
Cadwalader, Wickersham & Taft LLP, one of the world’s leading international law firms, acted as lead counsel to the Pfizer in the $68 billion cash and stock acquisition of Wyeth Inc., a transaction named Deal of the Year by Investment Dealer’s Digest (IDD).
The IDD Deal of the Year Awards issue recognizes the people and the companies who created the most value for their clients and investors. This year, the editors selected the top deals in 12 industry categories, including private equity, energy, healthcare, technology, telecommunications, financial institutions, real estate, industrial, media, retail, and restructuring.
“We are proud that in the challenging investment environment of 2009, we were able to assist clients, such as Pfizer, in developing the creative strategies needed to get their deals done and honored that IDD has recognized this significant transaction.” said Chris White, Cadwalader’s Chairman.
The Cadwalader team was led by partner Dennis Block and also included partners Dorothy Auth, Jason Halper, Steve Herman, Stewart Kagan, Jonathan Kanter, William Mills, Richard Nugent, Rick Rule, and Linda Swartz; special counsel Mark Holdsworth; and associates Ryan Andreoli, Joshua Apfelroth, Stephen Blank, Jonathan Bliley, Adam Brajer, Erika Engelson, Anna Erenburg, Cheryl Howard, Jonathan Karas, James Langston, Elizabeth Mattern, Braden McCurrach, Brendan O’Leary, Michael Rosado, Christopher Slimm, and Ariel Zell.
About Investment Dealers’ Digest
Investment Dealers’ Digest is designed to provide a forum for communication between all market participants – especially between the sell-side and the buy-side – which is crucial to the process of restoring the financial markets. In addition to the best of IDD’s industry-leading coverage of capital markets and key participants like hedge funds, private equity, and investment banking, every issue carries municipal market coverage from The Bond Buyer’s editorial staff.
Richard Brand, Brian McGovern
Joseph Moreno, Anne Tompkins
Robert Cannon will discuss the U.K.’s new insurance-linked securities framework.